SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Trading update

12 Jan 2022 07:00

RNS Number : 1353Y
Frontier IP Group plc
12 January 2022
 

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 ("MAR"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

RNS

AIM: FIPP

12 January 2022

 

 

 

Frontier IP Group plc

("Frontier IP" or the "Group")

 

Trading update

 

Frontier IP (AIM: FIPP), a specialist in commercialising intellectual property, is today providing a trading update ahead of publication of its interim results for the six months to 31 December 2021 ("H1 2022") which are expected to be released in March 2022. The Group has enjoyed a strong first half to the financial year in particular due to the IPO on the Nasdaq Global Select Market of portfolio company Exscientia plc ("Exscientia") during the period.

 

Exscientia reported a strong set of quarterly results post admission and, on 7 January 2022, announced a strategic research collaboration with Sanofi that will entitle Exscientia to an upfront cash payment of $100 million with the potential for $5.2 billion in total milestones plus tiered royalties. The uplift in book value of this holding as at 31 December 2021 is expected to make a significant contribution to the performance of the Group in H1 2022.

Further to the release of the Group's full year results in October 2021, Frontier IP has now commenced a programme to realise part of its shareholding in Exscientia. As at the date of this announcement a small portion has been sold in January 2022 and the Group will provide a further update at the appropriate time.

The Group's portfolio as a whole has continued to show strong commercial and technical progress and a number of the companies are reaching key inflection points. During the period The Vaccine Group announced encouraging data on the development of its next generation COVID-19 vaccine, Camgraphic completed a fundraising and management was strengthened at Pulsiv. This momentum is continuing into 2022 and yesterday we were pleased to note Celerum launching its Truck Logistics System at a time when supply chain challenges are high on the priority list for many businesses.

 

While it is clear there are many challenges facing markets and industry, we anticipate reporting a set of results for H1 2022 ahead of management expectations and continuing to build on progress in the balance of the financial year. We remain confident on the Group's prospects for the remainder of the financial year and beyond.

 

ENQUIRIES

 

Frontier IP Group Plc

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

T: 020 3968 7815 neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

 

T: 0203 328 5656

Singer Capital Markets (Broker)

Sandy Fraser / Harry Gooden / George Tzimas

T: 0207 496 3000

 

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUAORRURUAAUR
Date   Source Headline
26th May 20267:00 amRNS-RPortfolio news: Dekiln strategic partnership
5th May 20267:00 amRNSAppointment of Chief Financial Officer
16th Apr 20264:07 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSPortfolio News: 2D Photonics subsidiary grant
13th Apr 20262:35 pmRNSHolding(s) in Company
10th Apr 202610:30 amRNSUpdate re Investee Company
8th Apr 20267:00 amRNS-RPortfolio news – Fieldwork Robotics £3M fundraise
31st Mar 20265:18 pmRNSHolding(s) in Company
30th Mar 20267:00 amRNSUnaudited Half Year Results
23rd Mar 20267:00 amRNS-RAlusid reaches milestone in European roll out
28th Jan 20264:28 pmRNSHolding(s) in Company
19th Jan 20267:00 amRNS-RPortfolio news - Strong results for TVG vaccine
12th Jan 202610:30 amRNSHolding(s) in Company
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 202512:30 pmRNSResult of AGM
31st Dec 202512:30 pmRNSResult of AGM
29th Dec 20252:37 pmRNSHolding(s) in Company
29th Dec 20252:37 pmRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20257:00 amRNSHolding(s) in Company
23rd Dec 20252:17 pmRNSDirectors' Shareholdings
23rd Dec 20252:17 pmRNSDirectors’ Shareholdings
22nd Dec 20253:48 pmRNSResult of Retail Offer
22nd Dec 20253:48 pmRNSResult of Retail Offer
18th Dec 20259:15 amRNS-RDekiln benefits from £3 million funding
17th Dec 202511:54 amRNSResult of Placing and Subscription
17th Dec 20257:01 amRNSRetail Offer
17th Dec 20257:00 amRNSProposed Placing and Subscription to raise £870k
15th Dec 20257:00 amRNS-RPortfolio news- Alusid £500k pre-IPO funding round
10th Dec 20254:56 pmRNSHolding(s) in Company
9th Dec 20257:00 amRNSPosting of Annual Report & Notice of AGM
8th Dec 20257:00 amRNSFinal results for the year ended 30 June 2025
2nd Dec 20257:00 amRNS-RAlusid signs Swedish distribution agreement
6th Nov 20257:00 amRNSBord Change
3rd Nov 20257:00 amRNS-RTVG demonstrates success in animal trials
20th Oct 20257:00 amRNS-RAmprologix raises £740,000 in Pre-Series A round
25th Sep 20257:00 amRNSBoard Changes
24th Sep 20255:12 pmRNSHolding(s) in Company
13th Jun 20257:00 amRNSStrategic partnership for Cambridge innovation hub
10th Jun 20257:00 amRNS-RAlusid signs international distribution agreement
6th May 20257:00 amRNS-RTVG's vaccine candidate enters animal trials
16th Apr 20257:00 amRNS-RSyva signs option to license agreement with TVG
2nd Apr 20254:47 pmRNSDirector/PDMR Shareholding
31st Mar 20251:02 pmRNSDirector/PDMR Shareholding
26th Mar 20257:00 amRNSUnaudited Half Year Results
24th Mar 20257:00 amRNSCamGraphIC secures €25 million in Series A funding
18th Mar 20257:00 amRNS-RPulsiv wins PSMA’s Global Energy Efficiency Award
25th Feb 20257:00 amRNS-RGraphEnergyTech collaboration & Innovate UK grant

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.